Clinical Trials Logo

Filter by:
NCT ID: NCT02722161 Completed - Healthy Clinical Trials

Olmutinib (BI 1482694) ADME Study

Start date: April 2016
Phase: Phase 1
Study type: Interventional

To investigate the basic pharmacokinetics of BI 1482694, its metabolites M1 and M2, and [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1482694 given to healthy male volunteers

NCT ID: NCT02720367 Completed - Clinical trials for Urinary Bladder Cancer

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Start date: January 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors (TURBT)

NCT ID: NCT02720042 Completed - Hernia Clinical Trials

Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Start date: March 23, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to collect additional data on safety and performance of Phasix™ Mesh in subjects requiring Ventral Hernia Working Group (VHWG) Grade 3 midline hernia repair.

NCT ID: NCT02718898 Completed - Psoriasis Clinical Trials

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

IXORA-Q
Start date: April 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.

NCT ID: NCT02718378 Completed - Prostatic Neoplasms Clinical Trials

Evaluation of Safety and Efficacy of Estetrol in Healthy Men

Start date: March 2016
Phase: Phase 1
Study type: Interventional

The current study is designed as a phase Ib multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of E4 in healthy men after daily oral administration for 28 days.

NCT ID: NCT02716285 Completed - Clinical trials for Irritable Bowel Syndrome

Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery

PERSUADE
Start date: August 17, 2016
Phase: Phase 3
Study type: Interventional

Peppermint oil has shown to be effective in the treatment of Irritable Bowel Syndrome (IBS) symptoms in several meta-analyses. However, the level of evidence is moderate and peppermint oil remains relatively under-used in IBS. Therefore, the investigators will conduct a multicenter randomized, placebo controlled trial to investigate the effects of an eight-week peppermint oil treatment in IBS patients according to current European Medicines Agency (EMA) / US Food and Drug Administration (FDA) guidelines. To improve efficacy and to reduce side effects, the investigators aim to study the use of a new peppermint oil formulation, a colon-targeted-delivery capsule that will release the oil in the (ileo-) colonic region specifically.

NCT ID: NCT02716220 Completed - Clinical trials for Coronary Artery Disease

Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III)

BIOSOLVE-III
Start date: March 2016
Phase: N/A
Study type: Interventional

BIOSOLVE-III Study is a pre-market, prospective, multi-center trial to assess the acute clinical performance of the DREAMS 2G Drug-Eluting Coronary Scaffold in de novo coronary artery lesions.

NCT ID: NCT02716194 Completed - Hemophilia A Clinical Trials

BAX 826 Dose-Escalation Safety Study

Start date: March 3, 2016
Phase: Phase 1
Study type: Interventional

1. To assess tolerability and safety of BAX 826 after a single infusion in previously treated patients (PTPs) with severe hemophilia A 2. To determine the pharmacokinetic (PK) parameters of BAX 826 compared to ADVATE 3. To evaluate immunogenicity of polysialic acid linked to Factor VIII (FVIII)

NCT ID: NCT02715141 Completed - Colorectal Cancer Clinical Trials

Molecular Stool Testing for Colorectal Cancer Surveillance

MOCCAS
Start date: October 2015
Phase:
Study type: Observational

Rationale: Since January 2014 the Dutch screening programme for bowel cancer has been implemented. Screening will increase the demand for surveillance. Although patients in whom adenomas have been removed are at increased risk of progressing to cancer, solid evidence on the reduction of death from CRC through the current colonoscopy-based surveillance is lacking. Furthermore, colonoscopy-based surveillance leads to high logistic demands, high individual burden and high costs. Therefore, there is need for new surveillance strategies. Stool-based molecular testing (Cologuard®, consisting of a stool DNA test and an immunochemical assay for human hemoglobin) or Faecal Immunochemical Testing (FIT) may serve as an alternative for colonoscopy surveillance. The aim of this study is to compare the accuracy of an established molecular stool test (Cologuard®) and FIT to colonoscopy for detection of advanced adenomas or CRC (advanced neoplasia) in a surveillance population. These outcomes will be used to model various strategies of stool-based molecular surveillance to inform health policy decisions.

NCT ID: NCT02714218 Completed - Melanoma Clinical Trials

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Start date: April 4, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.